Chapter 20. Detecting and Quantifying Functional Inhibitors in Hemostasis

  1. Steve Kitchen PhD Clinical Scientist Scientific Director3,4,5,
  2. John D. Olson MD, PhD Professor Vice Chair for Clinical Affairs6 and
  3. F. Eric Preston MD, FRCPath, FRCP Emeritus Professor of Hematology Director7,8
  1. B. Verbruggen PhD1,
  2. I. Nováková MD, PhD2 and
  3. W. van Heerde PhD1

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303575.ch20

Quality in Laboratory Hemostasis and Thrombosis

Quality in Laboratory Hemostasis and Thrombosis

How to Cite

Verbruggen, B., Nováková, I. and van Heerde, W. (2009) Detecting and Quantifying Functional Inhibitors in Hemostasis, in Quality in Laboratory Hemostasis and Thrombosis (eds S. Kitchen, J. D. Olson and F. E. Preston), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303575.ch20

Editor Information

  1. 3

    Sheffield Hemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK

  2. 4

    UK National External Quality Assessment Scheme (EQAS) for Blood Coagulation, Sheffield, UK

  3. 5

    WHO and WFH International External Quality Assessment Programs for Blood Coagulation, Sheffield, UK

  4. 6

    Department of Pathology, University of Texas Health Science Center, San Antonio, Texas, USA

  5. 7

    University of Sheffield, Sheffield, UK

  6. 8

    WHO and WFH International External Quality Assessment Programs for Blood Coagulation, Rutledge Mews, Sheffield, UK

Author Information

  1. 1

    Central Laboratory for Hematology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

  2. 2

    Department of Hematology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 19 DEC 2008

ISBN Information

Print ISBN: 9781405168038

Online ISBN: 9781444303575

SEARCH

Keywords:

  • functional inhibitors of hemostasis – immunoglobulins interfering with blood coagulation;
  • screening tests for inhibitor detection;
  • inhibitors against individual coagulation factors;
  • clinical manifestations of hemostasis inhibitors;
  • European Concerted Action on Thrombophilia Foundation (ECAT);
  • UK National External Quality Assessment Scheme (NEQAS);
  • inhibitors against other clotting factors;
  • Acquired von Willebrand factor deficiency (AVWD);
  • substrate plasma type in factor VIII assay

Summary

This chapter contains sections titled:

  • Clinical manifestations of hemostasis inhibitors

  • Screening tests for inhibitor detection

  • Inhibitors against individual coagulation factors

  • Pitfalls and limitations of the inhibitor assay

  • Conclusions

  • References